PAIN MEDICINES WITH SPECIAL REFERENCE TO TRAMADOL
Abstract
Pain represents a significant medical and social problem because it affects daily functioning, as well as psychological, emotional and social well-being, causing significant economic and health problems. Pain control is one of the main goals of modern medicine, and the drugs used for this purpose are called analgesics. There is no one-size-fits-all medicine for every type of pain. That is why an individual approach to each patient is of key importance for the treatment and prevention of the recurrence of the disease. The aim is to demonstrate that the use of tramadol in relieving and reducing pain, with clearly defined indications, strictly controlled administration, precisely determined dosage and limited duration of use, can be an effective therapeutic option for the treatment of moderate and moderately severe pain when first-line medications are insufficiently effective or contraindicated. "The medicine is both medicine and poison at the same time!" When it is used according to the indications and instructions, it exerts its positive effect, and in the second case, when the indications, therapeutic doses, time intervals and length of therapy are not followed, it then exerts its negative effect. Healthcare professionals are required to assess the risk of addiction before starting therapy.
References
LITERATURA
National Academies of Sciences, Engineering, and Medicine. Compounded Topical Pain Creams: Review of Select Ingredients for Safety, Effectiveness, and Use. Schwinn DA, Jackson LM, editors. Washington (DC): The National Academies Press; 2020. doi: 10.17226/25689.
Lemke TL, Williams DA, editors. Foye's Principles of Medicinal Chemistry. 5th ed. Baltimore (MD): Lippincott Williams & Wilkins; 2002. Chapter 19, Opioid analgesics; p. 453-78.
Brunton LL, Lazo JS, Parker KL, editors. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 11th ed. New York: McGraw-Hill; 2006. Chapter 26, Analgesic-antipyretic agents; pharmacotherapy of gout; p. 671-716.
Ross JR, Riley J, Quigley C, Welsh KI. Clinical pharmacology and pharmacotherapy of opioid switching in cancer patients. Oncologist. 2006;11(7):765-73. doi: 10.1634/theoncologist.11-7-765.
Elliott KJ, Brodsky M, Hynansky A, Foley KM, Inturrisi CE. Dextromethorphan shows efficacy in experimental pain (nociception) and opioid tolerance. Neurology. 1995;45(12 Suppl 8):S66-8.
Ruscitto A, Smith BH, Guthrie B. Changes in opioid and other analgesic use 1995-2010: repeated cross-sectional analysis of dispensed prescribing for a large geographical population in Scotland. Eur J Pain. 2015;19(1):59-66. doi: 10.1002/ejp.520.
Araujo AM, Gómez M, Pascual J, Castañeda M, Pezonaga L, Borque JL. [Treatment of pain in the oncology patient]. An Sist Sanit Navar. 2004;27 Suppl 3:63-75.
Maltoni M, Scarpi E, Modonesi C, Passardi A, Sansoni E, Ruscelli P, et al. A validation study of the WHO analgesic ladder: a two-step vs three-step strategy. Support Care Cancer. 2005;13(11):888-94.
Varagić VM, Milošević MP. Farmakologija. 23. prerađeno i dopunjeno izd. Beograd: Elit Medica; 2012.
Raffa RB, Friderichs E, Reimann W, Shank RP, Codd EE, Vaught JL, et al. Complementary and synergistic antinociceptive interaction between the enantiomers of tramadol. J Pharmacol Exp Ther. 1992;260(1):275-85.
Albrecht E, Pereira P, Bazon V, Berger M, Wegrzyn J, Antoniadis A, et al. The relationship between postoperative opioid analgesia and sleep apnea severity in patients undergoing hip arthroplasty: a randomized, controlled, triple-blinded trial. Nat Sci Sleep. 2022;14:303-10. doi: 10.2147/NSS.S353342.
Crush J, Levy N, Knaggs RD, Lobo DN. Misappropriation of the 1986 WHO analgesic ladder: the pitfalls of labeling opioids as weak or strong. Br J Anaesth. 2023;130(1):e16-e17. doi: 10.1016/j.bja.2022.09.025.
VanAtta C, Perry LA, Crase A, Swierz A, Wenzinger S. Guidelines for the treatment of osteoarthritis. Findlay (OH): University of Findlay; 2023.
Lintz W, Beier H, Gerloff J. Bioavailability of tramadol after i.m. injection in comparison to i.v. infusion. Int J Clin Pharmacol Ther. 1999;37(4):175-83.
Dhesi M, Maldonado KA, Patel P, Maani CV. Tramadol. [Updated 2024 Feb 20]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024.
Gong L, Stamer UM, Tvetkov MV, Altman RB, Klein TE. PharmGKB summary: tramadol pathway. Pharmacogenet Genomics. 2014;24(7):374-80. doi: 10.1097/FPC.0000000000000057.
Dean L, Kane M. Tramadol Therapy and CYP2D6 Genotype. In: Pratt VM, Scott SA, Pirmohamed M, et al., editors. Medical Genetics Summaries [Internet]. Bethesda (MD): NCBI; 2015.
Grond S, Sablotzki A. Clinical pharmacology of tramadol. Clin Pharmacokinet. 2004;43(13):879-923. doi: 10.2165/00003088-200443130-00004.
Quinlan J, Macintyre PE. The pitfalls of labeling opioids as weak or strong. Comment on Br J Anaesth 2022;129:137-42. Br J Anaesth. 2022;129(6):e150-e153.
Radbruch L, Grond S, Lehmann KA. A risk-benefit assessment of tramadol in the management of pain. Drug Saf. 1996;15(1):8-29. doi: 10.2165/00002018-199615010-00002.
Dolan E, Delanty N. Tramadol use and risk of seizures: A report of two cases and a review of recent literature. Seizure. 2008;17(3):284-8.
Bakr MH, Radwan E, Shaltout AS, Farrag AA, Mahmoud AR, Abd-Elhamid TH, et al. Chronic exposure to tramadol induces cardiac inflammation and endothelial dysfunction in mice. Sci Rep. 2021;11:18772. doi:10.1038/s41598-021-98206-2.
Generes WM, Thomas S. Tramadol withdrawal symptoms, timeline and detox treatment. American Addiction Centers [Internet]. Updated 2025 Jan 17. Available from: https://americanaddictioncenters.org/opioids/tramadol/withdrawal-detox
Brackett CD, Duncan M, Wagner JF, Fineberg L, Kraft S. Multidisciplinary treatment of opioid use disorder in primary care using the collaborative care model. J Am Board Fam Med. 2022;35(1):240-244.